Mayo Clinic has signed on as one of three clinical sites for a federally funded project that aims to do something no gene therapy program has managed yet: build a single, reusable system to treat children with rare inherited immune disorders, rather than developing an expensive therapy for each mutation one at a time.
For families raising a child with an inborn error of immunity, the practical stakes are unusually concrete. These are conditions in which a faulty gene leaves a child susceptible to infections that healthy children shrug off. Treatment today often means lifelong antibody infusions, constant infection precautions, or a bone marrow transplant with its own serious risks.
Nothing in this announcement changes care available this year. No child can enroll today; no therapy has been tested in a person; and the project's stated goal is to treat ten children over five years. The reason it matters now is the design of the effort, not a result.
The Award and the Institutions Behind It
The project is called AEGIS, short for Affordable Gene Editing Therapies for Immune System Diseases of Children. It is funded by an award of up to $27.7 million from the Advanced Research Projects Agency for Health, the federal agency created to pursue high-risk medical research, and it is part of the agency's THRIVE program, which targets hereditary rare diseases with in vivo genetic medicines.
According to the ARPA-H award record, the prime awardee is the Innovative Genomics Institute at the University of California, Berkeley, the institute founded by CRISPR co-inventor Jennifer Doudna. Fyodor Urnov of the institute leads the project, and Donald Kohn of UCLA is lead principal investigator for the planned clinical trial.
Mayo Clinic announced its role this week, saying it will serve as one of three clinical sites, helping identify, enroll and care for children who might benefit. Avni Joshi, chair of Mayo's Division of Pediatric Allergy and Immunology, is the trial co-investigator there. "We hope to create therapies that not only treat disease but address its root cause," she said.
The other two treating centers are UCLA and the University of Utah, with Intermountain Primary Children's Hospital. The wider consortium adds Stanford, Princeton, the University of California San Diego, Emory, the Immune Deficiency Foundation, and the industrial partner Danaher. Inborn errors of immunity number more than 500 recognized disorders, and many have no curative therapy at all.
A Platform Instead of One Drug at a Time
The reason a platform matters comes down to arithmetic that currently makes these diseases commercially impossible. Roughly 500 disorders are associated with an estimated 20,000 disease-causing variants, and, according to the project team, fewer than half can be repaired with the current CRISPR toolbox. A conventional drug development program targets one variant, which means the market for any single therapy may be a handful of children worldwide.
The AEGIS approach, described in the Innovative Genomics Institute's announcement, combines base and prime editing with lipid nanoparticle delivery aimed at blood-forming stem cells in the bone marrow. Base and prime editing rewrite genetic letters without cutting both DNA strands, an approach researchers consider more precise than earlier methods.
The delivery method is the part worth understanding. Approved CRISPR therapies today work outside the body: stem cells are collected, edited in a laboratory, and returned after chemotherapy clears the patient's bone marrow. AEGIS is pursuing in vivo editing, meaning the editing tool is delivered directly into the body. Kohn described the vision as one in which "each child will have a personal gene editor administered via a simple injection."
Cost Is the Barrier the Project Is Actually Targeting
The affordability language in the project name is not decoration. Of the roughly 500 known inborn errors of immunity, only two currently have approved genetic treatments, and each costs well over $1 million per child while requiring extensive hospitalization. No in vivo CRISPR therapy for these conditions has been approved, and the team says there are no ongoing US clinical trials developing them.
The program's stated targets are a development timeline of under 3 months for personalized therapy and a per-patient cost below $200,000. Those are goals, not achievements, and they would still put treatment well outside the reach of most families without insurance coverage or public financing. But they would represent a substantial compression of both the timeline and the price relative to what exists.
American households encounter these diseases more often than the word rare suggests. Newborn screening for severe combined immunodeficiency is now standard in every state, which means families receive an abnormal result and a referral to an immunologist before symptoms appear. What follows that referral is where access problems begin, since pediatric immunology is concentrated in a small number of academic centers.
Ambition Set Against Results So Far
This is a funding announcement and a research plan. It is not a clinical trial result, a published study, or a regulatory filing. No safety or efficacy data exist for the AEGIS approach in humans, and lipid nanoparticle delivery to bone marrow stem cells remains technically difficult, though the team reports progress in mice and nonhuman primates.
The five-year target of ten treated children is the clearest signal of where the science actually stands. That is a first-in-human scale, appropriate for an untested approach and far from routine care. Families should treat any claim that a cure is imminent with skepticism.
Several questions remain open. No enrollment criteria have been released, no start date for first-in-human dosing has been announced, and federal awards of this kind are contingent on teams meeting milestones, meaning funding can be reduced or ended.
Families whose child has an inborn error of immunity should keep their current treatment plan unchanged and raise research questions with their immunologist rather than acting on an announcement. Mayo notes its membership in the Primary Immune Deficiency Treatment Consortium, and the Immune Deficiency Foundation, a consortium partner, maintains patient resources. Federal trial listings will be the first place any AEGIS study appears.
The verified takeaway is narrow. A federal agency has funded a serious attempt to make gene editing more repeatable and cheaper for a category of childhood diseases that have been effectively abandoned by conventional drug development, and a major clinical center has joined it. Whether it works is a question for the back half of this decade.
Key Questions Answered
What are inborn errors of immunity? A group of more than 500 rare genetic disorders, also called primary immunodeficiencies, in which a faulty gene leaves the immune system unable to work properly.
What is AEGIS trying to build? A reusable platform for creating personalized CRISPR treatments, rather than a single therapy for a single mutation.
Can my child enroll in a trial now? No. No clinical trial has opened, and no enrollment criteria have been published.
How is this different from approved CRISPR therapies? Approved therapies edit cells outside the body and require chemotherapy to clear the bone marrow. AEGIS is pursuing editing inside the body through injection.
How much would treatment cost? The program's target is under $200,000 per patient. The two existing approved genetic treatments for these conditions each cost well over $1 million.
Has any of this been tested in people? Not through this program. No human safety or efficacy data exist for the AEGIS approach.
What should families do now? Keep current treatment unchanged and discuss research questions with a pediatric immunologist rather than acting on a funding announcement.
